Aligos Therapeutics: Funding, Investors & Team (Oct 2026)
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Aligos Therapeutics has raised $281M across 3 funding rounds on record, the most recent an undisclosed round of $105M announced in Feb 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aligos Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Aligos Therapeutics Funding Rounds
Aligos Therapeutics raised $83.6M in a Post-IPO Equity announced in Jul 2021.
2.3 years later, an undisclosed round of $92.0M was announced in Oct 2023.
1.3 years later, an undisclosed round of $105M was announced in Feb 2025.
Aligos Therapeutics Founders and Leadership Team
Contact details for the Aligos Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Aligos Therapeutics Funding Compared to Other Biotechnology Startups
Aligos Therapeutics' latest round of $105M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aligos Therapeutics in Biotechnology and San Francisco
Companies Similar to Aligos Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Aligos Therapeutics Funding FAQs
What does Aligos Therapeutics do?
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
How much funding has Aligos Therapeutics raised?
Aligos Therapeutics has raised $281M across 3 rounds on record. The most recent is an undisclosed round of $105M announced in Feb 2025.
When did Aligos Therapeutics last raise funding?
Aligos Therapeutics' most recent funding round on record is an undisclosed round of $105M, announced in Feb 2025.
Who is the CEO of Aligos Therapeutics?
Lawrence Blatt is listed as CEO at Aligos Therapeutics.
Where is Aligos Therapeutics headquartered?
Aligos Therapeutics is based in San Francisco, California, United States.
How many employees does Aligos Therapeutics have?
Aligos Therapeutics is in the 101-250 employee band.
How does Aligos Therapeutics' funding compare to other Biotechnology startups?
Aligos Therapeutics' latest round of $105M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Aligos Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aligos Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.